Drug targets identification and pathways modulation STUDIES during the generation of drug-resistant models.

DTI-Tech, a Swiss biotech company focused on innovative drug target identification and resistance modeling technologies, proposes IFDREAM (Integrate Functional Drug-REsponse mApping systeM), a proprietary platform designed to help pharmaceutical and biotechnology companies accelerate oncology drug development and better predict resistance mechanisms during preclinical research.

The IFDREAM platform by DTI-Tech integrates two innovations: 1) a novel drug target identification (DTI) approach and 2) rapid generation of resistance models. This dual platform enables early detection of target relevance and drug resistance mechanisms, improving decision-making over fragmented methods and supporting the development of therapies to overcome resistance in patients.

Unique Selling Proposition: DTI-Tech’s unique selling proposition is the combined application of drug target identification and rapid generation of resistant cancer models. While competitors offer target ID services using alternative methods, no companies currently provides newly generated resistant models integrated with target engagement and pathway analysis.

The Problem: There is a critical medical need to rapidly uncover the mechanism of action of drug-like small molecules and to quickly predict and overcome drug resistance in cancer models made resistant to given therapies.

The Solution: DTI-Tech addresses the problem through its IFDREAM platform combining DTI and resistant models, enabling earlier identification of resistance mechanisms and more effective therapeutic strategies.